The mechanism: In August 2025, HHS terminated BARDA's mRNA vaccine portfolio — 22 contracts worth roughly $500 million, including the flagship $766 million (cumulative) award to Moderna for an H5N1 mRNA bird-flu vaccine. Secretary Robert F. Kennedy Jr. framed it as a platform judgment, not a budget cut: BARDA will still fund pandemic preparedness, but it now prefers whole-virus and protein-subunit vaccines over mRNA. That is a procurement-policy decision, and it moves money exactly like the tariff or antitrust calls this newsletter tracks — it just moved it away from the company most investors assumed would win it.

That is the real story, and it is bigger than any single quarter of COVID sales: BARDA is not just a grant-maker, it is the government's biodefense customer-of-first-resort, and being cut from that list is a durable headwind, not a one-time headline.